Citigroup Inc. downgraded shares of AbbVie Inc. (NYSE:ABBV) from a buy rating to a neutral rating in a research note issued to investors on Monday morning.

A number of other analysts have also weighed in on the stock. Vetr lowered shares of AbbVie from a strong-buy rating to a buy rating and set a $67.75 price objective on the stock. in a research note on Monday. Leerink Swann reiterated a hold rating on shares of AbbVie in a research note on Tuesday, November 8th. BMO Capital Markets restated a market perform rating and set a $63.00 price target on shares of AbbVie in a research report on Tuesday, November 8th. Jefferies Group restated a buy rating and set a $90.00 price target on shares of AbbVie in a research report on Tuesday, November 1st. Finally, Credit Suisse Group AG lowered shares of AbbVie from an outperform rating to a neutral rating and dropped their price target for the company from $70.00 to $60.00 in a research report on Monday, October 31st. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $69.82.

Shares of AbbVie (NYSE:ABBV) opened at 59.46 on Monday. The stock has a market capitalization of $96.63 billion, a PE ratio of 16.07 and a beta of 1.55. The stock’s 50 day moving average is $60.41 and its 200 day moving average is $62.70. AbbVie has a 12 month low of $50.71 and a 12 month high of $68.12.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 28th. The company reported $1.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.20 by $0.01. The firm had revenue of $6.43 billion for the quarter, compared to analyst estimates of $6.55 billion. AbbVie had a net margin of 24.08% and a return on equity of 150.77%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.13 earnings per share. Analysts anticipate that AbbVie will post $4.82 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/29/abbvie-inc-abbv-downgraded-to-neutral-at-citigroup-inc.html.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 15th. Shareholders of record on Friday, January 13th will be paid a dividend of $0.64 per share. The ex-dividend date is Wednesday, January 11th. This is an increase from AbbVie’s previous quarterly dividend of $0.57. This represents a $2.56 dividend on an annualized basis and a yield of 4.23%. AbbVie’s payout ratio is 61.62%.

In other AbbVie news, insider Laura J. Schumacher sold 50,000 shares of AbbVie stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $65.00, for a total transaction of $3,250,000.00. Following the transaction, the insider now directly owns 144,138 shares of the company’s stock, valued at $9,368,970. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.11% of the company’s stock.

A number of institutional investors have recently modified their holdings of the company. Capital Research Global Investors increased its position in shares of AbbVie by 100.6% in the second quarter. Capital Research Global Investors now owns 152,718,713 shares of the company’s stock worth $9,439,710,000 after buying an additional 76,593,054 shares during the period. Nisa Investment Advisors LLC increased its position in shares of AbbVie by 18.9% in the second quarter. Nisa Investment Advisors LLC now owns 631,940 shares of the company’s stock worth $39,123,000 after buying an additional 100,674 shares during the period. RNC Capital Management LLC increased its position in shares of AbbVie by 1.2% in the second quarter. RNC Capital Management LLC now owns 620,340 shares of the company’s stock worth $38,405,000 after buying an additional 7,057 shares during the period. Atalanta Sosnoff Capital LLC purchased a new position in shares of AbbVie during the second quarter worth approximately $20,759,000. Finally, Bank of Montreal Can purchased a new position in shares of AbbVie during the second quarter worth approximately $93,942,000. 66.67% of the stock is currently owned by institutional investors.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions.

5 Day Chart for NYSE:ABBV

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.